View in EDS

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.

Saved in:
Bibliographic Details
Title: Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.
Authors: Perimbeti S; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Hematology and Medical Oncology, Penn State Cancer Institute, Hershey, PA, USA., Jamroze A; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Gopalakrishnan D; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Hematology and Oncology, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE., Jain R; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Division of Hematology and Oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY, USA., Jiang C; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Hematology and Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Holleran JL; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Parise RA; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Bies R; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York at Buffalo, Buffalo, NY, USA.; Institute for Computational and Data Sciences, University at Buffalo, State University of New York at Buffalo, Buffalo, NY, USA., Quinn D; Abbvie, South San Francisco, CA, USA., Attwood K; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Liu X; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Green K; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Kirk JS; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Beumer JH; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA.; Department of Oncology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, USA., Tang DG; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Dean.Tang@Roswellpark.org.; Experimental Therapeutics Graduate Program, University at Buffalo and Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Dean.Tang@Roswellpark.org., Chatta G; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Gurkamal.Chatta@Roswellpark.org.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2025 Nov 29; Vol. 95 (1), pp. 115. Date of Electronic Publication: 2025 Nov 29.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41315064
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Perimbeti+S%22">Perimbeti S</searchLink>; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Hematology and Medical Oncology, Penn State Cancer Institute, Hershey, PA, USA.<br /><searchLink fieldCode="AU" term="%22Jamroze+A%22">Jamroze A</searchLink>; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.<br /><searchLink fieldCode="AU" term="%22Gopalakrishnan+D%22">Gopalakrishnan D</searchLink>; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Hematology and Oncology, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.<br /><searchLink fieldCode="AU" term="%22Jain+R%22">Jain R</searchLink>; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Division of Hematology and Oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Jiang+C%22">Jiang C</searchLink>; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Hematology and Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Holleran+JL%22">Holleran JL</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Parise+RA%22">Parise RA</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Bies+R%22">Bies R</searchLink>; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York at Buffalo, Buffalo, NY, USA.; Institute for Computational and Data Sciences, University at Buffalo, State University of New York at Buffalo, Buffalo, NY, USA.<br /><searchLink fieldCode="AU" term="%22Quinn+D%22">Quinn D</searchLink>; Abbvie, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Attwood+K%22">Attwood K</searchLink>; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.<br /><searchLink fieldCode="AU" term="%22Liu+X%22">Liu X</searchLink>; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.<br /><searchLink fieldCode="AU" term="%22Green+K%22">Green K</searchLink>; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.<br /><searchLink fieldCode="AU" term="%22Kirk+JS%22">Kirk JS</searchLink>; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.<br /><searchLink fieldCode="AU" term="%22Beumer+JH%22">Beumer JH</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA, USA.; Department of Oncology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, USA.<br /><searchLink fieldCode="AU" term="%22Tang+DG%22">Tang DG</searchLink>; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Dean.Tang@Roswellpark.org.; Experimental Therapeutics Graduate Program, University at Buffalo and Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Dean.Tang@Roswellpark.org.<br /><searchLink fieldCode="AU" term="%22Chatta+G%22">Chatta G</searchLink>; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Gurkamal.Chatta@Roswellpark.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227806519%22">Cancer chemotherapy and pharmacology</searchLink> [Cancer Chemother Pharmacol] 2025 Nov 29; Vol. 95 (1), pp. 115. <i>Date of Electronic Publication: </i>2025 Nov 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>7806519 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0843 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203445704%22">03445704 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Chemother Pharmacol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41315064
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00280-025-04840-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 115
    Titles:
      – TitleFull: Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Perimbeti S
      – PersonEntity:
          Name:
            NameFull: Jamroze A
      – PersonEntity:
          Name:
            NameFull: Gopalakrishnan D
      – PersonEntity:
          Name:
            NameFull: Jain R
      – PersonEntity:
          Name:
            NameFull: Jiang C
      – PersonEntity:
          Name:
            NameFull: Holleran JL
      – PersonEntity:
          Name:
            NameFull: Parise RA
      – PersonEntity:
          Name:
            NameFull: Bies R
      – PersonEntity:
          Name:
            NameFull: Quinn D
      – PersonEntity:
          Name:
            NameFull: Attwood K
      – PersonEntity:
          Name:
            NameFull: Liu X
      – PersonEntity:
          Name:
            NameFull: Green K
      – PersonEntity:
          Name:
            NameFull: Kirk JS
      – PersonEntity:
          Name:
            NameFull: Beumer JH
      – PersonEntity:
          Name:
            NameFull: Tang DG
      – PersonEntity:
          Name:
            NameFull: Chatta G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 29
              M: 11
              Text: 2025 Nov 29
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0843
          Numbering:
            – Type: volume
              Value: 95
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Cancer chemotherapy and pharmacology
              Type: main
ResultId 1